Stephanie Piazzola
BofA Securities, Research Division

[Audio Gap] I cover medical devices at Bank of America. And next up as part of our health care conference, we have CeriBell. We have Jane Chao, CEO; and Scott Blumberg, CFO. So thank you both for being here today.

Xingjuan Chao
Co-Founder, President, CEO & Director

Thank you for having us.

Stephanie Piazzola
BofA Securities, Research Division

Maybe we can start with Q1 since you just reported the other day, revenue came in a little better than the Street, and it was our largest quarter of net new adds and record usage per account. So maybe you can just give some background on the commercial progress you've been making on both fronts to get to these record levels in Q1.

Scott Blumberg
Chief Financial Officer

Sure, Stephanie. As you alluded, there's really 2 core drivers for our core seizure market. I know I'm sure we'll get into the pipeline soon. But one is accounts added and two is usage per account. On the account adds front, we added 33 accounts in Q1, which brings us up to 680 total. It was our largest number of new adds since we've become a public company. That continues to grow, and we see growth drivers there, accelerators in the maturation of the sales force as well as initiatives we have like our expansion from the VA system.

And then on the other side of the house, that's usage per account. We don't disclose that specifically, but we do disclose product revenue per account. So I know